06.23.25 -- Is An Outsourced BD Model Gaining Traction At CDMOs?

With over 30+ years of experience, Catalent offers a comprehensive suite of orthogonal GMP analytical services for all biological modalities, from discovery to commercial phases. Our seasoned experts ensure exceptional on-time delivery and client satisfaction by providing tailored solutions to meet your unique needs—no matter the complexity, scale, or timeline. Watch our intro video to learn more about our capabilities!

In response to a 2023 Open Letter from leading pharma companies, CDMOs are determining how to adapt their SOPs to improve sustainability and reduce CO2 emissions.

Did you know that FDA recalls have increased 115% since 2018? Learn more on how to avoid common recall mistakes and effective recovery strategies for your company today.

Explore how to select the right CDMO partner for your pharmaceutical project to navigate the evolving drug development landscape and ensure successful outcomes.

As the timeline for commercialization closes in, it’s necessary to best position the organization for a successful launch. Where to start?

Examine a unique model to predict injection force designed to decorrelate factors linked to formulation development and the ones linked to container and delivery device selection.

Discover the process conditions and protocols that were chosen as optimization targets and the resulting improvements to ADC production and purification that assessing these parameters provided.

A structured approach integrating technical expertise, advanced process solutions, and scalable infrastructure can address the challenges of multispecific antibody development and manufacturing.

Review a strategy for overcoming challenges when acquiring new equipment for an Emergency Use Authorization (EUA) project, and how leveraging existing resources and collaboration was key.

Witness how high-throughput biologic automation and GMP master cell banking services, as well as variable selection services that search the SQL space to find promoters.

Enhance your injectable projects with our expertise and expanded capacity to meet the demand for vials, pre-filled syringes, and cartridges from pre-clinical development to commercial launch.

Integrated development and manufacturing solutions for mammalian-based biologics, including mAbs, ADCs, and biosimilars, with strong quality, flexibility, and regulatory compliance.

Achieve cost-efficient monoclonal antibody purification with MabSelect™ SuRe 70 — our highest-capacity, alkaline-stable protein A resin designed for rapid cycling and consistent performance.

Speed up your program with end-to-end microbial and mammalian biologics development and manufacturing expertise — spanning everything from biosimilars to vaccines.

Detra Glinatsis, Vice President of Business Development, presents the advanced capabilities, strategic growth, and expanding capacity of Northway Biotech, a global biologics CDMO.